MedicalDevice Licensing.com
Pharmalicensing.com
Latest: Watch here for details of new products and services.
RSS Feeds
Advanced search

Login  Register

About Us
Pharmalicensing - Partnering solutions for the life sciences
 
Our Products
Overview
Partnering Search
Company Profiling
Deal Negotiation
PL Intelligence
Reports
Comparison
 
PL Intelligence
Overview
Industry news
Deals review
Press releases
Articles
 
Case Studies
See what others think about our service
 
Newsletter
Partnering update
Key reports
Subscribe
 
Quick Links
Profile now
Register now
Profiled companies
Featured events
Industry news
PR Newswire
Jobs
 
Contact Pharmalicensing
Send an email
Call us: +44 1904 520460
Request a callback
 
RSS Feeds
Keep up to date

Pharmalicensing
is a division of
UTEK Europe Ltd
UTEK Corporation
Companies

Navamedic

Navamedic is a Scandinavian specialty pharma company focusing on registration and marketing. Therapeutic areas include OA, Medical Nutrition, Oral Medicine, Female Care, Addictions and Dermatology.

The company in detail

Summary

Navamedic ASA traces its roots back to 1997, when the company co-founder and current CEO, Øyvind Brekke, while a student at the Norwegian Technical University in Trondheim (NTNU) developed a new and improved production method for glucosamine HCl. The company was founded a few years later in 2001 inIceland with the intention of becoming a production company of chitin and glucosamine. In 2002, the Norwegian holding company, which today holds 100% of the Icelandic subsidiary, was founded. Around the same time, the company entered into an agreement with Weifa AS, a leading Norwegian pharmaceutical company, to co-develop a glucosamine pharmaceutical product. This agreement enabled Navamedic to pursue a vertical integration strategy in the glucosamine value chain. In 2003, the company teamed up with Hydro Organics, a reputed contract research organisation, in order to refine and further develop the "Brekke-Method". In 2003, the Navamedic development project also qualified for "Skattefunn", a public tax refund programme for R&D projects.

R&D

To view this information, you must subscribe to PL Intelligence.

Deals

To view this information, you must subscribe to PL Intelligence.

Senior management

To view this information, you must subscribe to PL Intelligence.

Board of directors

To view this information, you must subscribe to PL Intelligence.

Clients in focus...

Get the Flash Player to see this rotator.

Partnering and licensing intelligence in life sciences industry
Press releases: Pharmalicensing current industry press releases.

© Copyright 1995-2009 Pharmalicensing, a division of UTEK Europe Ltd UTEK Corporation All rights reserved. Terms and Conditions | Contact us